Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Tongjitang Chinese Medicine Reaches De-listing Deal

publication date: Nov 2, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Tongjitang Chinese Medicines will be taken private by group comprised of its Chairman and Fosun Industrial at a price of $4.50 per ADS. The offer was originally made in April of this year. The result was never really in doubt, as Xiaochun Wang, Chairman and CEO of Tongjitang, owns 51% of the company, and Fosun controls 32%, giving them a combined 83% stake in the company. More details....

Stock Symbol: (NYSE: TCM)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors